Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard(Institut Gustave Roussy), Egbert F. Smit(Vrije Universiteit Amsterdam), Harry J.M. Groen(University of Groningen), Julien Mazières(Université Toulouse III - Paul Sabatier), Benjamin Besse(Institut Gustave Roussy), Åslaug Helland(Oslo University Hospital), Vanessa Giannone(Novartis (United States)), Anthony M. D’Amelio(Novartis (United States)), Pingkuan Zhang(Novartis (United States)), Bijoyesh Mookerjee(Novartis (United States)), Bruce E. Johnson(Dana-Farber Cancer Institute)
The Lancet Oncology
September 11, 2017
10.1016/s1470-2045(17)30679-4
Cited by 1,362Open Access
Full Text

Abstract

Related Papers

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al.|New England Journal of Medicine|2015|9.4k
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al.|New England Journal of Medicine|2015|6.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais et al.|The Lancet Oncology|2012|5.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al.|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al.|New England Journal of Medicine|2014|3.2k